Prothena Corporation plc
Moat Score — Prothena Corporation plc
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Prothena's proprietary CYTOPE platform for discovering antibodies against misfolded protein conformations has independently drawn three major partnerships (Roche, Novo Nordisk, BMS) worth up to roughly $3 billion in aggregate milestones, strong third-party validation of the underlying IP, though it has not yet translated into any approved, revenue-generating product. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a small clinical-stage biotech with no manufacturing or commercial infrastructure of its own, Prothena has no cost advantage; it relies entirely on larger partners (Roche, Novo Nordisk, BMS) to fund and run the expensive late-stage trials and future manufacturing for its most advanced programs. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | Prothena has no marketed products and therefore sets no prices; FY2025 total revenue was only $9.7 million, almost entirely a one-time BMS collaboration milestone rather than product sales, so pricing power does not yet exist as a moat source. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Drug discovery and clinical development create no mechanism by which additional patients, prescribers, or partners make Prothena's existing assets more valuable to others; there is no network effect in this business. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Prothena's big-pharma partners (Roche, Novo Nordisk, BMS) are bound into long-dated, deeply negotiated licensing and collaboration agreements covering specific molecules, which creates some structural stickiness, but this is partner-contract lock-in rather than a true customer switching cost since Prothena has no end-customer base of its own. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Prothena operates in the high-cost, high-barrier niche of rare peripheral amyloid and neurodegenerative disease drug development, where pivotal trial costs (its PARAISO and CLEOPATTRA Phase 3 programs run into the thousands of patients) are themselves a barrier to new entrants, though Prothena does not dominate this niche and depends on partners to bear most of that cost. |